Loading
A phase 2 trial of Roginolisib in uveal melanoma, run by iOnctura, active and no longer recruiting.
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma is a phase 2 interventional study registered as NCT06717126 by iOnctura, with 85 participants enrolled, started 2025-02-27 and due to reach its primary completion in 2027-12. Interventions recorded: roginolisib and Investigator choice of standard therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/